Exclusive: Campaign group calls on institutional shareholders to vote against re-election of bosses overseeing net zero row-back Bank chairs who water down their lenders’ climate commitments this year ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

The funding discussions highlight ongoing investor demand for new and unproven research labs looking to find novel approaches to AI that push the technology forward. Recursive’s goal is to develop ...